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Possible role for CD4O-CD4OL in the regulation of interstitial infiltra-
tion in the kidney. Interstitial infiltration by mononuclear cells is a
hallmark of most inflammatory kidney diseases, and the degree of
infiltration is associated with disease progression. It has been demon-
strated that proximal tubular epithelial cells (PTEC) are an important
source of different cytokines/chemokines and thereby play a central role in
the regulation of the local inflammatory response. CD4O is a cell surface
receptor involved in immune regulation for which the ligand is expressed
on activated T cells. By different staining methods, CD4O was found
expressed in cryosections on the basolateral side of tubuli, as well as on the
surface of an SV4O-transformed PTEC line (PTEC-TRL) and on primary
PTEC cultures. Cross linking CD4O receptor on these cultured cells, using
a CD4OL-transfected mouse fibroblast, resulted in strong up-regulation of
the production of the chemokines IL-8, MCP-1 and RANTES. For IL-8
and MCP-1 production, the stimulation index after CD4O activation
ranged from two- to sevenfold. Much stronger effects were observed for
RANTES production, where levels remained undetectable (< 0.1 ng/ml)
in non-stimulated cultures, whereas CD4O activation resulted in a strong
production reaching 5 ng/ml in a 72-hour culture period. These data
suggest that CD4OL-CD40 interactions between infiltrating activated T
cells and PTEC might be an important factor in the regulation of
interstitial infiltration within the kidney.
Most chronic human kidney diseases are characterized by
progressive loss of renal function. It is thought that this progres-
sion results from a pathogenic process that is independent of the
original etiology, functioning as a final common pathway [1—3].
Initially, this final common pathway is characterized by the
triggering of interstitial infiltration and the induction of tubular
damage. As a consequence, tubular cells can become activated
and begin to express several cytokines!growth factors, adhesion
molecules and extracellular matrix components [4, 1. Overpro-
duction of these matrix components results in fibrosis, which
ultimately leads to permanent loss of normal integrity and func-
tion of the kidney.
During these processes, inflammatory cells, such as CD4 and
CD8 T cells, monocytes/macrophages, and to a lesser extent B
cells and dendritic cells are recruited into the inflamed intersti-
tium [6—9]. In recent years it has become clear that chemokines,
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locally produced at sites of inflammation, are of major importance
for the regulation of cellular infiltration. The large family of
chemokines can be divided in subfamilies with regard to structural
characteristics, receptor usage and target cell specificity [10, 11].
C-X-C chemokines (cr-chemokines; like IL-8) are mainly chemo-
tactic for PMN's, whereas C-C chemokines (f3-chemokines; like
MCP-1, RANTES) are preferentially chemotactic for mononu-
clear cells.
Both in vitro and in vivo studies have demonstrated that tubular
epithelial cells may form a prominent source for the production of
inflammatory mediators, including chemokines. Either constitu-
tively, or after activation, proximal tubular epithelial cells (PTEC)
have been shown to produce IL-8 [12, 13], monocyte chemotactic
protein (MCP-1) [14—16] and RANTES [17, 18]. As chemokine
production by PTEC can be an important regulatory mechanism
for interstitial infiltration, a major question is how this chemokine
production is regulated. Several studies have demonstrated the
stimulatory effect of proinflammatory cytokines, like IL-i, TNFa
and IFNy on chemokine production [12—15, 18]. In addition, it has
been suggested that other factors like ischemia and "protein
overload" might have a direct effect on chemokine production
[19].
CD4O is a 50 kDa glycoprotein that has been initially described
on the surface of B lymphocytes and belongs to the TNF-R
superfamily [20]. Construction of CD4O-Ig chimeric molecules
allowed the identification and cloning of a ligand for CD4O
(CD4OL), which is mainly expressed on the surface of activated
CD4 T cells [21]. In vitro, CD4O activation results in important
effects on B cell growth, differentiation and isotype switching
[22—251. The important in vivo role of CD4O has been demon-
strated in patients with the X-linked hyper-IgM syndrome
(HIUM) who have mutations in their CD4OL gene and who lack
a secondary immune response, as shown by the lack of isotype
switching and the absence of memory B cells [26, 271.
In recent years it has become clear that CD4O is not exclusively
expressed on B cells, but is also present on other hematopoietic
and non-hematopoietie cells, including monocytes, dendritic cells,
endothelial cells, fibroblasts and epithelial cells [20, 28—381. The
functional consequence of CD40 activation on these cells are
diverse and include enhanced survival, phenotypic changes, ex-
pression of adhesion and co-stimulatory molecules and the in-
duced/enhanced production of different cytokines [25].
We hypothesized that in situations where T cells are infiltrating
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Fig. 1. Morphological appearance of cultured proximal tubular epithelial cells (PTEC). Cultured PTEC show the charateristic morphology as described
by Detrisac et al [421.
the interstitial area of the kidney, there might be a direct
interaction between activated T cells and PTEC, possibly involv-
ing CD4O-CD4OL. In the present study, CD4O expression could be
demonstrated on PTEC by various methods. Functional experi-
ments, by using a co-culture system which mimics this T-PTEC
interaction, specifically enhanced the production of different
chemokines by PTEC. This suggests a role for this receptor-ligand
pair in the regulation of the local inflammatory response, and
provides an additional mechanism by which production of chemo-
kines can be regulated.
Methods
Cell cultures
L cells. Mouse fibroblast L cells, stably transfected with human
CD4OL, have been previously described [391. In brief, mouse Ltk
cells were transfected with an SRs-promoter based expression
plasmid [40], containing the complete human CD4OL coding
sequence and a neomycin resistance gene for selection of stable
transfectant. Non-transfected cells were used as the negative
control. Both types of L cells were cultured in IMDM glutamax
(Gibco/Life Technologies, Paisley, Scotland, UK), supplemented
with 10% heat-inactivated FCS (FCS; Life Technologies Inc.,
Gaitheresburg, MD, USA) and penicilin/streptomycin (Gibco/
Life).
Proximal tubular epithelial cells (PTEC). Primary human proxi-
mal tubular epithelial cell (PTEC) lines were cultured from cortex
tissue of human kidneys not suitable for transplantation because
of anatomical reasons or from healthy nephrectomy specimens
[41, 421. PTEC monolayers were cultured in a selective medium,
consisting of a 1:1 ratio of DMEM and Ham F12 (both from
Seromed Biochem KG, Berlin, Germany), supplemented with
insulin (5 jxg/ml), transferrin (5 j.g/ml), selenium (5 ng/ml),
hydrocortisone (36 nglml), tri-iodothyronine (40 pg/mI) and epi-
dermal growth factor (10 ng/ml) (all from Sigma Chemical Co., St.
Louis, MO, USA). The first passage of cells was grown on a matrix
of collagen type I (Sigma) and FCS, whereas further cell growth
was maintained on culture flasks coated with zFCS only. For
passage of the cultures, cells were harvested by trypsinization with
0.02% (wt/vol) EDTAJO.05% (wt/vol) trypsin (Sigma). Outgrowth
of PTEC was confirmed by morphological appearance and immu-
nofluorescence staining, as described [411. Briefly, cells were
stained with specific monoclonal antibodies, including anti-cyto-
keratin, anti-EMA (epithelial membrane antigen) and anti-ade-
nosine deaminase binding protein/CD26. Furthermore, cultures
formed monolayers (Fig. 1), as well as "domes," which indicate
the potential to grow in a polarized fashion and retain the
maintenance of pumping capacities. The life span of these pri-
mary cultures is limited and reaches a maximum of 10 passages.
Primary cell lines were used for experiments between passages 2
and 7 of culture.
For initial experiments, a transformed PTEC line was used.
This cell line (PTEC-TRL) has been generated by transfection
with a plasmid containing the SV4O large-T antigen. The gener-
ation of these cells, as well as the functional comparison with the
parental, non-transformed, cell line is described in more detail
elsewhere (J.S.J. Gerritsma, manuscript submitted for publica-
tion). The life span of these cells was prolonged to minimally 30
passages, and the cells were demonstrated to retain the original
characteristics. However, cells seemed to be "hyperactive," as
shown by the much stronger production of several cytokines.
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Fig. 2. FACS analysis of PTEC-TRL. SV4O-transformed PTEC (PTEC-TRL) were cultured as described in the Methods section, harvested with EDTA
and stained for the following surface molecules: (A) CD4O (mAb89), (B) MHC class I and (C) CD26IADBP. Staining was developed with a
goat-anti-mouse-PE conjugate and compared with an irrelevant antibody. The left-hand histograms represent the staining with control antibodies.
These transformed cells were cultured as described above, and
were used between passages 12 and 19.
Coculture experiments
For cocultures, trypsinized PTEC and trypsinized L cells were
mixed in suspension in a 1:1 ratio, unless indicated otherwise.
Cells were cultured in complete DMEM/Ham F12 medium in a
volume of 1 ml and in a final PTEC concentration of 1 X i0
cells/ml. L cells were irradiated (80 Gy), to prevent overgrowth of
the cultures by these fibroblasts. Experiments with B lymphocytes
have shown that irradiation does not inhibit the CD4OL activating
capacity [22, 39]. Supernatants were harvested after 72 hours of
culture, unless indicated otherwise, and frozen prior to analysis of
cytokine production.
Antibodies and other reagents
For staining procedures and cultures the following antibodies
were used: two different anti-CD4O antibodies mAb89 [43] and
G28-5 [44], anti-CD4OL antibody LL2, generated against the
above described transfectants [45]. All antibodies were of the
IgGi isotype, and therefore an isotype matched IgGI with
non-related specificity was used in control experiments. Further-
more, staining was performed with anti-MHC class I antibody
W6-32 and the anti-CD26/ADBP antibody 1071, as described [41].
To study CD4O activation in the absence of murine fibroblasts,
we made use of a soluble CD4OL molecule. Generation and
production of this soluble CD8n-CD4OL chimeric molecule has
been described before [39]. The construction of the fusion protein
containing the extracellular regions of mouse CD8a and human
CD4OL was chosen for several reasons. The mouse CD8s has
been demonstrated to have no interaction with human MHC class
I, thereby excluding other cellular interactions with human cells.
In addition, mouse CD8cs forms dimers and thereby facilitates
CD4O receptor cross linking.
Determination of cytokine production
Production of cytokines by cultured epithelial cells was mea-
sured in the culture supernatants by immunoassays specific for
human cytokines.
For IL-8 measurements, a similar sandwich ELISA as described
for IL-6 was used [46], with monoclonal anti-IL-8 (CLB, Amster-
dam, the Netherlands) as the capturing antibody and a polyclonal
anti-IL-8 antiserum [13] as the detection antibody.
For RANTES measurements, a sandwich ELISA was per-
formed utilizing monoclonal and polyclonal antibodies against
human RANTES (R&D Systems, Minneapolis, MN, USA), with
recombinant hRANTES as a standard (PeproTech, London, UK)
For detection of MCP-1 production, an inhibition radioimmu-
noassay was used, as described before [15].
FACS analysis
For FACS experiments, PTEC were harvested with 2.5 mwi
EDTA in PBS to prevent proteolysis of the surface receptors. The
whole staining procedure was performed in staining buffer con-
taining 1% BSA (Sigma), 1% human serum and 0.02% sodium
azide in PBS. Primary antibodies were added in a final concen-
tration of 5 j.tg/ml, incubated for 30 minutes, washed three times
with staining buffer, followed by incubation with a second anti-
body goat-anti-mouse Ig-PE (DAKO, Glostrup, Denmark). Cell
fluorescence was measured on a FACScan (Becton Dickinson,
Mountain View, CA, USA), and data were analyzed with the
LYSIS program.
Staining procedures
Coverslips. Trypsinized PTEC were grown for two days on glass
coverslips that had been coated with LFCS. Cells were fixed for 10
minutes with 200 sl 100% ethanol at room temperature, washed
twice with PBS, followed by an incubation step with the primary
antibody in a final concentration of 10 sgIml. The reaction was
followed by HRP-conjugated rabbit-anti-mouse Ig (DAKO) and
developed by the addition of FITC-Tyramides, as described [47].
Staining was analyzed by fluorescence microscopy.
Kidncy ctyosections. Biopsies of different kidney specimen were
snap-frozen, cut into 4 j.m sections and stained with the AEC
method. Briefly, sections were fixed in 100% acetone, stained with
primary antibody at 10 sg/ml, followed by HRP-conjugated
rabbit-anti-mouse and swine-anti-rabbit-HRP (both from DAKO)
and developed using a 5% 3-amino-9-ethyl carbazol (AEC;
Sigma) solution. Stainings were analyzed by light microscopy.
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Fig. 3. IL-8 production by activated PTEC-TRL. SV4O-tansformed PTEC
(PTEC-TRL) (10 cells/mi) were cultured either alone or in combination
with control L cells (lOs cells) or CD4OL-transfected L cells (10 cells).
After 72 hours, supernatants were harvested and tested for IL-8 produc-
tion in a specific ELISA. Data indicated are of two different experiments
and show the mean production (± SD) of triplicate cultures.
Results
CD4O is expressed on a SV-40-transformed PTEC line
To test the presence of the CD4O molecule on human tubular
epithelial cells, a transformed cell line (PTEC-TRL) was tested
for CD4O expression. FACS analysis showed that these cells have
a strong homogeneous expression of CD4O (Fig. 2). Similar results
were obtained with two different CD4O antibodies (mAb89 and
G28-5), and during different passages of this cell line (data not
shown). For comparison, staining for MHC class I and CD26/
adenosine deaminase binding protein, a marker expressed on
tubular epithelial cells, is shown (Fig. 2).
Functional consequence of CD4O cross linking
Knowing that CD4O is expressed on transformed PTEC, we
wondered whether CD4O cross linking could also transmit signals
to these epithelial cells. For this reason, human PTEC were
cocultured with CD4OL-transfected mouse fibroblasts which are
very efficient for the activation of human B lymphocytes [22, 39].
Since PTEC can produce pro-inflammatory cytokines, we investi-
gated whether IL-8 production was modified after CD4O activa-
tion. Figure 3 shows that, in two different experiments, PTEC-
TRL cells displayed low spontaneous production of IL-8 (17 and
47 ng/ml), which was minimally changed upon coculturing with
control, non-transfected L cells (10 and 37 ng/mI). In contrast,
upon coculture with CD4OL-transfected L cells (ratio 1:1), PTEC
were induced to secrete high levels of IL-8 (492 and 730 ng/ml,
respectively).
As shown in Figure 4, the production of IL-8 (Fig. 4A) was
maximal for a 1:1 ratio, though a significant increase of IL-8 can
still be seen with a 1:9 ratio of L-CD4OL cells and PTEC. Control
L cells did not induce enhanced cytokine production under any of
the cell concentrations tested (data not shown).
The stimulatory effect of cytokine production was specific of the
CD4OL-CD40 interaction since blocking antibodies against
CD4OL were able to inhibit the secretion of IL-S (Fig. 4B).
Dilution of the blocking antibodies resulted in a recovery of the
CD4O-induced response (data not shown). Isotype matched con-
trol antibodies (IgGi) at a concentration of 10 sg/ml were
ineffective in this inhibitory effect.
Fig. 4. Dose response effect of CD4O-L-transfected L cells. (A) SV40-
tansformed PTEC (PTEC-TRL) (10 cells/mi) were cultured with io
control L cells, or varying concentrations of CD4O-L-transfected L cells
(100, 33, 11 x i0 cells, respectively). Supernatants were harvested after
72 hours of culture and tested for IL-8 production. Data shown are the
mean production (± SD) of triplicate cultures, and are representative of
three experiments. (B) SV4O-tansformed PTEC (PTEC-TRL) were cul-
tured as decribed above, in the presence of control L cells or CD4O-L-
transfected L cells with the addition of no antibody, anti-CD40-L (LL2),
or a control IgGI antibody, as indicated. Antibodies were added at the
beginning of the culture in a final concentration of 10 g/ml. After 72
hours, supernatants were tested for IL-8 production. Data shown are the
mean (± SD) of triplicate cultures and are representative of three different
experiments.
CD4O is expressed on primary PTEC line,c
The expression and function of CD4O on primary, non-trans-
formed, PTEC cultures was then investigated. Flow cytometry
analysis of 10 PTEC lines, between passages 2 and 7, in all eases
showed a homogeneous expression of CD4O (Fig. 5 and Table 1).
No major difference in CD4O expression could be identified in
these cells tested, which were derived from different tissue
specimens. CD4O expression could also be demonstrated by
staining with a soluble chimcric molecule [39], consisting of the
extracellular regions of human CD4OL and mouse CD8s (data
not shown).
PTEC grown over coverslips also showed strong CD4O staining,
thus indicating that expression of CD4O was not a consequence of
a cellular stress caused by the detachment procedure (Fig. 6).
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Although all cells stain positive for CD4O, the molecule appears
not to be equally distributed over the membrane. The stronger
staining at the edges, combined with the fact that these cells grow
polarized (with their apical site up), might suggest that CD4O is
stronger expressed at the basal/basolateral site of PTEC.
CD4O-activation of primary PTEC enhances chemokine
production
The functional role of CD4O on PTEC primary cell lines was
subsequently analyzed using CD4OL-transfected L cells as a
trigger. In these experiments we concentrated on the production
of different chemokines, as an important regulatory mechanism
for interstitial infiltration. As shown in Figure 7, CD4O activation
of primary PTEC cell lines resulted in an increased production of
lL-8, MCP-1 and RANTES. The study of six independent cell
lines showed that, over a 72-hour culture period, chemokine
production was enhanced two- to sevenfold for IL-S and two- to
fivefold for MCP-1. For RANTES, we observed no detectable
production under non-stimulated conditions (< 0.1 nglml). After
CD4O activation, strong induction of RANTES production was
observed, ranging from 1.0 to 5.1 nglml (range of 6 different
experiments). The quantity of IL-8 detected was much lower than
observed with the transformed cell line (Fig. 3). Similar quanti-
tative differences have been observed by comparison of the
transformed cell line with the parental non-transformed cells
(J.S.J. Gerritsma et a!, submitted for publication).
Maximal induction of chemokine secretion was found in a 1:1
ratio of L cells and PTEC, with a significant induction still
observed for a 1:9 ratio. (Fig. 8A). Non-transfected L cells are not
able to enhance the spontaneous cytokine secretion of primary
PTEC. In these figures MCP-i production is shown, but similar
results were obtained for IL-S and RANTES. When cultures were
followed in time, strong IL-8 and RANTES production could
already be detected after 48 hours of culture (Fig. 8B). Active
production continued over a longer period of time, and was still
present after 120 hours. Even after 120 hours of culture, no
RANTES production could be detected under non-stimulated
conditions.
Specificity of CD4O activation is demonstrated by blocking
antibodies as well as by a stimulatoiy soluble CD4OL molecule
The specificity of chemokine production after CD4O activation
is confirmed by the complete inhibition of RANTES, MCP-1 and
IL-8 production after addition of blocking antibodies against
CD4OL and CD4O (Fig. 9). Similar concentrations of a control
IgGi monoclonal antibody showed no effect on this production.
To exclude a possible contribution of the murine fibroblasts in
the CD4O-mediated activation, we also tested a soluble CD4OL
molecule. We could demonstrate that both IL-8, MCP-l and
RANTES production were also enhanced by a soluble CD4OL-
CD8a chimeric molecule (Table 2). In this chimeric protein, the
murine CD8a part dirnerizes and serves to cross link the CD4O
receptor, whereas it is known to have no interaction with human
MHC class I {39J.
CD4O can be detected on human iubular epithelial cells in situ
The expression of CD4O on cryosections from different kidney
specimens was then analyzed by immunohistochemistry. CD4O
was only very weakly expressed on either tubuli or other renal
structures of normal kidney sections (Fig. bA). However, on
some tubuli staining of CD4O can be observed (Fig. lOB; indicated
by arrows). On these positive tubuli, the CD4O molecule seemed
mostly located at the basal or basolateral side of the epithelial
cells. Taking into consideration the fact that all cultured cells are
positive for CD4O, as determined by FACS analysis, these data
suggest that CD4O expression can be up-regulated under certain
conditions.
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Table 1. Expression of CD4O on different PTEC lines
Fig. 5. FACS analysis of prilnaty PTEC lines
Primaiy PTEC lines were cultured as described in
the Methods section, haivested with EDTA and
stained for CD4O (mAb89). Staining was
developed with a goat-anti-mouse-PE conjugate
and compared with an irrelevant antibody (A,
histograms). Representative data of PTEC-1
and PTEC-2 from Table I are shown.
Different PTEC lines were investigated for CD4O expression by FACS
analysis. Data indicated are the mean fluorescence intensities of staining
with either a control antibody or with the CD4O antibody mAb89. FACS
profiles of PTEC-1 and PTEC-2 are shown in Fig. 5.
Fig. 6. Fluorescent staining of adherent PTEC cells. PTEC cells (PTEC-8) were grown on glass coverslips and directly stained with either a control IgGi
antibody (A), or the CD4O antibody mAh89 (B), using the Tyramide-FITC method as described in the Methods section.
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Fig. 7. (A) IL-8, (B) MCP-1 and (C) RANTES production by D4O-activaied primary PTEc. PTEC (1O cells/mi) were cultured either alone or in
combination with control L cells (1O cells) or CD4OL-transfcctcd L cells (lOs cells), as indicated. After 72 hours, supernatants were harvested and tested
for TL-8 (A), MCPl (B) and RANTES (C) production. Results shown are representative for six different PTEC lines, and data shown are the mean
production (± SD) of triplicate cultures.
Discussion
The present study describes the functional expression of the
CD4O molecule on cultured human kidney proximal tubular
epithelial cells, both on a transformed cell line as well as on
primary cell cultures. Cross linking of CD4O, by using a CD4OL-
transfected mouse fibroblast L cell, resulted in enhanced produc-
tion of several chemokincs (IL-8, MCP-1, RANTES) by these
epithelial cells. It should be stressed that these experiments are
facilitated by the fact that PTEC arc of human and fibroblasts of
murine origin. Specificity of this response could be shown by the
use of untransfected fibroblasts, by a soluble CD8cs-CD4OL
chimera and by neutralizing antibodies. This indicates that the
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thymectomy or treatment with various anti-T cell antibodies, is
beneficial in different models of kidney diseases [501. The func-
tional importance of these infiltrating T cells is relatively poorly
explored. Cytokines produced by activated T cells (IL-2, IFNy)
are capable of directly activating PTEC [41, 51, 52]. Our present
results show that also direct cellular interactions might play a
functional role. Activated T cells, attracted into the interstitium,
induce the production of chemokines, which thereby regulate the
further attraction and maintenance of cellular infiltration. This
suggests that there is a positive activation ioop in the regulation of
interstitial infiltration.
Although many groups have studied signal transduction mech-
anisms of CD4O, either at the level of associated molecules,
intracellular second messengers or induced transcription factors,
no deferiitive model yet exists [251. Furthermore, these studies
have mainly concentrated on B lymphocytes. It cannot be cx-
cluded that other mechanisms are operational in epithelial cells,
or in the regulation of chemokine production.
Especially our finding of RANTES production after CD4O
activation is of major importance. RANTES is an important
chemoattractant for T lymphocytes [53]. Until now, induction of
RANTES production, either by bronchial epithelial cells or
endothelial cells, has been restricted to the cytokines IL-i, TNFcs
and IFNy [54, 55]. Interestingly, we observed a fast kinetics and
very strong induction of RANTES production (Fig. 8B). This
seems in accordance with the results in endothelial cells and
bronchial epithelial cells [54, 55], but contrasts the original
findings in T lymphocytes [56]. The induction of RANTES
production has been associated with renal allograft rejection [17].
Finally, it now becomes clear that RANTES might also have
direct stimulatory effects on T cells [57]. Therefore, CD4O-
induced RANTES production might be an important part of the
interstitial inflammatory process.
96 120 Expression of CD4OL is mainly restricted to activated T lym-
phocytes [21]. Activation of T cells could occur locally by inter-
action with either infiltrating monocytes or with PTEC. PTEC
express MHC class I and class II, and in vitro T cells can be grown
from kidney biopsies that are able to specifically lyse PTEC in a
CytotoXicity assay [58, 59]. This raises the possibility that PTEC
can function as antigen presenting cell (APC), as suggested before
[60—621. Recent experiments have demonstrated that CD4O-
CD4OL interactions might play an important role in this cross talk
between T cells and APC [63, 64]. In this respect, it is interesting
that all (semi-) professional APCs, like dendritic cells, monocytes,
B cells or endothelial cells, do express CD4O [25]. In addition, it
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Fig. 8. CD4O-induced chemokine production is dose and time dependent.
PTEC (10 cells/mi) were cultered with i0 control L cells, or varying
concentrations of CD4O-L-transfected L cells (100, 33, 11 X iO cells,
respectively). Supernatants were harvested after 72 hours of culture and
tested for MCP-1 production (A). Data shown are the mean production
(± so) of triplicate cultures, and are representative of two different
experiments. PTEC were cultured in the presence of control L cells or
CD4O-L-transfected L cells, and supernatants were harvested after differ-
ent periods of time, as indicated. Supernatants were tested for IL-8 (B)
and RANTES (C) production. Data shown are the mean production of
duplicate cultures, and are representative of experiments with three
different cell lines. Note that the quantities of chemokines produced are
different from Figure 7. This is caused by the fact that different PTEC lines
are used in these experiments.
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interaction between activated T cells and tubular epithelial cells
might play an important role in the regulation of local inflamma-
tory responses.
Infiltration of mononuclear cells into the interstitial area is a
general phenomenon observed in various inflammatory kidney
diseases [6-9, 48, 49]. It has been demonstrated that functional
inhibition of T cell function, either by cyclosporine A treatment,
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Table 2. Cytokine production induced by a CD4OL-CD8a chimeric
protein
Cytokine production ng/ml
IL-8 MCP-1 RANTES
Control 9.0 (0.4) 3.3 (0.5) <0.1
Soluble CD4OL 13.0 (0.6) 27.7 (0.5) 2.2 (0.2)
PTEC were cultured in either mock-transfected medium, or with a
CD4OL-CD8a chimeric protein, as described [391. Supernatants were
harvested after 72 hours of culture and tested for IL-8, MCP-1 and
RANTES production as indicated. Data shown are the mean of triplicate
cultures (with SD in parenthesis).
Fig. 9. CD4O-induced chemokine production is inhibited by specific anti-
bodies: (A) MCP-1; (B) RANTES; (C) IL-8. PTEC were cultured in the
presence of control L cells or CD4O-L-transfected L cells with the addition
of no antibody, anti-CD4O-L (LL2), anti-CD4O (mAb89) or a control IgGI
antibody, as indicated. Antibodies were added at the beginning of the
culture in a final concentration of either 10, 2, 0.4 or 0.08 i.g/ml, as
indicated. Supernatants were tested for RANTES and MCP-1 production.
Data shown are the mean (± so) of duplicate cultures and are represen-
tative of three different experiments.
was recently demonstrated that simultaneous blocking of CD4O-
CD40L and CD28-B7 prevented both heart and skin allograft
rejection [65].
An important question concerns the in vivo regulation of CD4O
expression. Immunohistochemical analysis suggested that CD4O is
only expressed at low levels in normal kidneys. A similar finding of
CD4O staining on some individual tubuli was recently reported by
another group (Dr. HE. Feucht, presented at 2nd EKRF meet-
ing, Baveno, Italy, May 24—27, 1996). In the case of IgAN, an
up-regulation of CD4O on vascular endothelium was also observed
(data not shown). This is in accordance with recent studies where
CD4O could be demonstrated on endothelium in skin and muscle
sections, or on cultured HUVEC [32—34]. On cultured PTEC,
there is a high constitutive CD4O expression, suggesting that the
selective and rich medium, necessary for outgrowth of these
epithelial cells, already induced this expression. Alternatively,
there might be an active repression of CD4O expression in the in
vivo situation. At variance with thymie epithelial cells [36], CD4O
expression on PTEC was not up-regulated after incubation with
IL-la, TNFa or IFNY (data not shown). Therefore, further
studies are needed to determine the nature of signals regulating
CD40 expression.
The expression of surface receptors on epithelial cells is not
always equally distributed over the membrane. For example, the
family of surface peptidases, which play a role in protein degra-
dation and resorption, are mainly expressed on the apical brush
border side [66]. Here we have shown that CD4O seems to be
located mainly at the basal side (Fig. 6 and Fig. lOB), which fits
with a role in cellular interaction with infiltrating interstitial T
cells. We have analyzed kidney sections for CD4OL expression,
but were unable to distinguish any positive staining on infiltrating
T cells (data not shown). This does not come as a surprise,
inasmuch as detection of CD4OL within secondary lymphoid
organs has been difficult and still represents a matter of contro-
versy [67—69]. This is likely the consequence of the very strict
regulation of CD4OL expression on activated T cells [70, 71].
Alternatively, it is possible that alternative ligands to CD4O may
exist, which could be either surface receptors or extracellular
matrix proteins as shown for other members of the TNF-R family
[72, 73].
In conclusion, we have demonstrated that kidney PTEC arc
able to express CD4O both in vitro and in vivo, and that in vitro
activation via this receptor leads to enhanced production of
various chemokines. These findings might lead to new therapeutic
strategies to interfere with ongoing inflammatory disease pro-
cesses. In recent years, in several disease models like collagen
induced arthritis [74], graft versus host disease [75], pancreatic
islet allograft transplantation [76] and nephritis [77, 78], blocking
the CD4O-CD4OL interaction have been demonstrated to inter-
fere with ongoing disease processes. Since CD4O is expressed
much broader than on B cells only, the mechanisms of these
treatments might not only include blocking of functional T-B cell
interaction, but also the interference with other cellular interac-
tions like T-monocyte, T-synoviocyte or T-epithelial cell interac-
tions.
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Fig. 10. Immunohistochemical analysis of CD4O
expression in kidney sections. Cryosections were
stained for CD4O expression with the AEC
method. Shown are biopsies of a kidney of a
normal donor (A, magnification X250). In the
high power field (B, magnification X400)
positive staining for CD4O is indicated by
arrows.
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